Early data suggest KLN-1010, now acquired by Eli Lilly, could be more tolerable but less efficacious that AstraZeneca’s ...

This webinar will highlight how circular RNA overcomes key challenges in in vivo CAR-T therapy, with case examples from YXgene’s circRNA platform. In vivo CAR-T therapy is emerging as a transformative ...

Capstan Therapeutics scientists demonstrate that lipid nanoparticles can engineer CAR T cells within the body without laboratory cell manufacturing and ex vivo expansion. The method using targeted ...

Kelonia Therapeutics has shared the largest slice of data yet for its in vivo CAR-T, helping to justify the $3.2 billion price tag that Eli Lilly recently paid to buy the Boston biotech. All 18 ...

Lilly’s $7bn acquisition of Kelonia seems to be bearing fruit, with other in vivo approaches showing promise.

A method called "in vivo CAR-T (in vivo CAR-T·in vivo CAR-T)" that directly alters immune cells within the body with a single injection is recently transforming the cancer treatment market. This ...

Legend Biotech said Tuesday all six patients in a Phase 1 study of its in vivo CAR-T responded to the lymphoma treatment.

Introducing the first in vivo data using RetroT, a first-in-class all-mRNA platform for stable gene delivery without viral components Demonstrating CREATE's leadership in in vivo immune cell ...

Please provide your email address to receive an email when new articles are posted on . The first four patients dosed achieved early MRD-negative bone marrow. No grade 3 or higher hematologic toxicity ...

ROCHESTER, Minn., December 23, 2025--(BUSINESS WIRE)--Vyriad, Inc., a clinical-stage biotechnology company developing targeted genetic therapies for cancer and other serious diseases, today announced ...